Armistice Capital, LLC and Steven Boyd filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 3,872,000 shares of Voyager Therapeutics, Inc. common stock as of September 30, 2026.

Key Highlights

  • Beneficial ownership: Armistice Capital, LLC and Steven Boyd each reported beneficial ownership of 3,872,000 shares of Voyager Therapeutics common stock.
  • Percent of class: The 3,872,000 shares represent 6.28% of the outstanding class, according to the filing.
  • Shared voting and dispositive power: Both reporting persons reported 0 shares with sole voting or dispositive power, and 3,872,000 shares with shared voting and shared dispositive power.
  • Direct holder: The filing states the shares are directly held by Armistice Capital Master Fund Ltd., with Armistice Capital, LLC serving as investment manager under an Investment Management Agreement.
  • Event date: The date of the event requiring the filing was September 30, 2026.
  • Ordinary course certification: The reporting persons certified the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

Armistice Capital and Steven Boyd Disclose Position in Voyager Therapeutics Common Stock

According to the Schedule 13G filed on November 16, 2026, Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 3,872,000 shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) common stock, par value $0.001 per share (CUSIP: 92915B106). The filing identifies the event triggering the disclosure as occurring on September 30, 2026. Voyager Therapeutics is headquartered at 75 Hayden Avenue, Lexington, MA 02421, according to the filing.

The filing states that Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd., described as the direct holder of the shares. Pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities held by the Master Fund and thus may be deemed to beneficially own those securities. Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to beneficially own the same securities. The filing further notes that "the Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital."

Both reporting persons are listed at 510 Madison Avenue, 7th Floor, New York, New York 10022. Armistice Capital, LLC is organized in Delaware; Steven Boyd is a United States citizen. The filing was signed by Steven Boyd in his capacity as Managing Member of Armistice Capital, LLC and in his individual capacity, both dated November 16, 2026. A joint filing statement pursuant to Rule 13d-1(k) was included as an exhibit.

What Was Disclosed

Armistice Capital, LLC and Steven Boyd filed a Schedule 13G disclosing that, as of September 30, 2026, they beneficially own 3,872,000 shares of Voyager Therapeutics, Inc. common stock, representing 6.28% of the class, all held with shared voting and dispositive power through Armistice Capital Master Fund Ltd.